Literature DB >> 3496802

CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia.

C M Banki, G Bissette, M Arato, L O'Connor, C B Nemeroff.   

Abstract

To further investigate the hypothesis that hyperactivity of the hypothalamic-pituitary-adrenal axis in patients with depression may be mediated by hypersecretion of corticotropin-releasing factor (CRF), the authors measured CRF-like immunoreactivity in CSF samples from 138 neurological control, 54 depressed, and 27 nondepressed (23 schizophrenic and four manic) subjects. The CSF CRF concentration was markedly higher (almost twofold) in depressed patients than in control subjects and nondepressed psychiatric patients. The concentration of CSF CRF was slightly but significantly higher in schizophrenic patients than in control subjects. These findings provide further support for the hypothesis that CRF hypersecretion occurs in major depression.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496802     DOI: 10.1176/ajp.144.7.873

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  42 in total

1.  Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor.

Authors:  M L Price; I Lucki
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.

Authors:  J D Bremner; J Licinio; A Darnell; J H Krystal; M J Owens; S M Southwick; C B Nemeroff; D S Charney
Journal:  Am J Psychiatry       Date:  1997-05       Impact factor: 18.112

Review 3.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

Review 4.  Cellular and molecular mechanisms of sexual differentiation in the mammalian nervous system.

Authors:  Nancy G Forger; J Alex Strahan; Alexandra Castillo-Ruiz
Journal:  Front Neuroendocrinol       Date:  2016-01-11       Impact factor: 8.606

Review 5.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

6.  Interaction between the effects of corticotropin-releasing factor and prepulse parameters on prepulse inhibition in two inbred rat strains and the F1 generation of a cross between them.

Authors:  Lisa H Conti; Jane E Sutherland; Carey M Muhlhauser
Journal:  Behav Brain Res       Date:  2009-06-08       Impact factor: 3.332

7.  Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone.

Authors:  G E Duncan; D J Knapp; S W Carson; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

8.  Estrogen-mediated effects on depression and memory formation in females.

Authors:  Tracey J Shors; Benedetta Leuner
Journal:  J Affect Disord       Date:  2003-03       Impact factor: 4.839

Review 9.  The CRF system, stress, depression and anxiety-insights from human genetic studies.

Authors:  E B Binder; C B Nemeroff
Journal:  Mol Psychiatry       Date:  2009-12-15       Impact factor: 15.992

10.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.